Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components

Jennifer W. Bea, Peter Jurutka, Elizabeth A. Hibler, Peter Lance, Maria E. Martínez, Denise J. Roe, Christine L. Sardo Molmenti, Patricia A. Thompson, Elizabeth T. Jacobs

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aim Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. Methods Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n = 1048) and 25(OH)D (n = 2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. Results A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend < 0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend < 0.001), and low high-density lipoprotein (p-trend < 0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend < 0.01), high waist circumference (p-trend < 0.04) and triglyceride levels (p-trend < 0.01). Participants with 25(OH)D ≥ 30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. Conclusion These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.

Original languageEnglish (US)
Pages (from-to)447-459
Number of pages13
JournalMetabolism: Clinical and Experimental
Volume64
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Vitamin D
HDL Lipoproteins
Triglycerides
Waist Circumference
LDL Lipoproteins
Blood Glucose
Epidemiologic Studies
Cross-Sectional Studies
Clinical Trials
Blood Pressure
Neoplasms

Keywords

  • 1,25(OH)2D
  • 25(OH)D
  • Metabolic syndrome
  • Vitamin D

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components. / Bea, Jennifer W.; Jurutka, Peter; Hibler, Elizabeth A.; Lance, Peter; Martínez, Maria E.; Roe, Denise J.; Sardo Molmenti, Christine L.; Thompson, Patricia A.; Jacobs, Elizabeth T.

In: Metabolism: Clinical and Experimental, Vol. 64, No. 3, 01.03.2015, p. 447-459.

Research output: Contribution to journalArticle

Bea, JW, Jurutka, P, Hibler, EA, Lance, P, Martínez, ME, Roe, DJ, Sardo Molmenti, CL, Thompson, PA & Jacobs, ET 2015, 'Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components', Metabolism: Clinical and Experimental, vol. 64, no. 3, pp. 447-459. https://doi.org/10.1016/j.metabol.2014.11.010
Bea, Jennifer W. ; Jurutka, Peter ; Hibler, Elizabeth A. ; Lance, Peter ; Martínez, Maria E. ; Roe, Denise J. ; Sardo Molmenti, Christine L. ; Thompson, Patricia A. ; Jacobs, Elizabeth T. / Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components. In: Metabolism: Clinical and Experimental. 2015 ; Vol. 64, No. 3. pp. 447-459.
@article{be7b96469584472f9b1ded469623024f,
title = "Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components",
abstract = "Aim Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. Methods Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n = 1048) and 25(OH)D (n = 2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. Results A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95{\%} CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend < 0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend < 0.001), and low high-density lipoprotein (p-trend < 0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend < 0.01), high waist circumference (p-trend < 0.04) and triglyceride levels (p-trend < 0.01). Participants with 25(OH)D {\^a}‰¥ 30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95{\%} CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. Conclusion These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.",
keywords = "1,25(OH)2D, 25(OH)D, Metabolic syndrome, Vitamin D",
author = "Bea, {Jennifer W.} and Peter Jurutka and Hibler, {Elizabeth A.} and Peter Lance and Mart{\'i}nez, {Maria E.} and Roe, {Denise J.} and {Sardo Molmenti}, {Christine L.} and Thompson, {Patricia A.} and Jacobs, {Elizabeth T.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.metabol.2014.11.010",
language = "English (US)",
volume = "64",
pages = "447--459",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Concentrations of the vitamin D metabolite 1,25(OH)2D and odds of metabolic syndrome and its components

AU - Bea, Jennifer W.

AU - Jurutka, Peter

AU - Hibler, Elizabeth A.

AU - Lance, Peter

AU - Martínez, Maria E.

AU - Roe, Denise J.

AU - Sardo Molmenti, Christine L.

AU - Thompson, Patricia A.

AU - Jacobs, Elizabeth T.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Aim Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. Methods Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n = 1048) and 25(OH)D (n = 2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. Results A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend < 0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend < 0.001), and low high-density lipoprotein (p-trend < 0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend < 0.01), high waist circumference (p-trend < 0.04) and triglyceride levels (p-trend < 0.01). Participants with 25(OH)D ≥ 30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. Conclusion These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.

AB - Aim Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. Methods Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n = 1048) and 25(OH)D (n = 2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. Results A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend < 0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend < 0.001), and low high-density lipoprotein (p-trend < 0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend < 0.01), high waist circumference (p-trend < 0.04) and triglyceride levels (p-trend < 0.01). Participants with 25(OH)D ≥ 30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. Conclusion These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.

KW - 1,25(OH)2D

KW - 25(OH)D

KW - Metabolic syndrome

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84921810251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921810251&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2014.11.010

DO - 10.1016/j.metabol.2014.11.010

M3 - Article

VL - 64

SP - 447

EP - 459

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -